Back to Authors

Hermann, Joerg

Mayo Clinic

Mayo Clinic

Citations 4

Education in cardio-oncology: the next frontiers
Farmakis, Dimitrios , Hermann, Joerg, López‐Fernández, Teresa , Herrmann, Joerg , López-Fernández, Teresa , Lyon, Alexander R.

European Heart Journal | June 7, 2024 | Volume: 45 | Issue: 27 | Pages: 2352-2354

10.1093/eurheartj/ehad895 Get It

Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents
Johnson, Isla McKerrow , Karrar, Omer , Rana, Masooma , Iftikhar, Moazah, Chen, Sunny , Saliba, Antoine N. , Al‐Kali, Aref , Begna, Kebede H. , Litzow, Mark R. , Patnaik, Mrinal M. , Pardanani, Animesh , Hermann, Joerg, Tefferi, Ayalew , Gangat, Naseema , Saliba, Antoine N. , Johnson, Isla M, Saliba, Antoine N , Al-Kali, Aref , Alkhateeb, Hassan B , Shah, Mithun V , Pardanani, Animesh , Tefferi, Ayalew , Gangat, Naseema , Saliba, Antoine N , McCullough, Kristen , Alkhateeb, Hassan B. , Hogan, William J. , Shah, Meera

British Journal of Haematology | February 5, 2024 | Volume: 204 | Issue: 4 | Pages: 1232-1237

10.1111/bjh.19325 Get It

SummaryAmong 301 newly diagnosed patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent, 23 (7.6%) experienced major cardiac complications: 15 cardiomyopathy, 5 non‐ST elevation myocardial infarction and/or 7 pericarditis/effusions. Four patients had more than one cardiac complication. Baseline characteristics included median age ± interquartile range; 73 ± 5 years; 87% males; 96% with cardiovascular risk factors; and 90% with preserved baseline ejection fraction. In multivariate analysis, males were more likely (p = 0.02) and DNMT3A‐mutated cases less likely (p < 0.01) to be affected. Treatment‐emergent cardiac events were associated with a trend towards lower composite remission rates (43% vs. 62%; p = 0.09) and shorter survival (median 7.7 vs. 13.2 months; p < 0.01). These observations were retrospectively retrieved and warrant further prospective examination.
The Impact of Radiation Dose to Heart Substructures on Major Coronary Events and Patient Survival after Chemoradiation Therapy for Esophageal Cancer
Wang, Xin , Hobbs, Brian P. , Nead, Kevin T. , Yusuf, Syed Wamique , Hermann, Joerg, Lin, Steven H. , Lin, Steven H , Palaskas, Nicolas L , Abe, Jun-Ichi , Yusuf, Syed Wamique , Deswal, Anita M

Cancers | March 3, 2022 | Volume: 14 | Issue: 5 | Pages: 1304

10.3390/cancers14051304 Get It

Background: There is a paucity of data regarding the association between radiation exposure of heart substructures and the incidence of major coronary events (MCEs) in patients with esophageal cancer (ESOC) undergoing chemoradiation therapy. We studied radiation dosimetric determinants of MCE risk and measured their impact on patient prognosis using a cohort of ESOC patients treated at a single institution. Methods: Between March 2005 and October 2015, 355 ESOC patients treated with concurrent chemoradiotherapy were identified from a prospectively maintained and institutional-regulatory-board-approved clinical database. Dose-distribution parameters of the whole heart, the atria, the ventricles, the left main coronary artery, and three main coronary arteries were extracted for analysis. Results: Within a median follow-up time of 67 months, 14 patients experienced MCEs at a median of 16 months. The incidence of MCEs was significantly associated with the left anterior descending coronary artery (LAD) receiving ≥30 Gy (V30Gy) (p = 0.048). Patients receiving LAD V30Gy ≥ 10% of volume experienced a higher incidence of MCEs versus the LAD V30Gy < 10% group (p = 0.044). The relative rate of death increased with the left main coronary artery (LMA) mean dose (Gy) (p = 0.002). Furthermore, a mutual promotion effect of hyperlipidemia and RT on MCEs was observed. Conclusion: Radiation dose to coronary substructures is associated with MCEs and overall survival in patients with ESOC. In this study, the doses to these substructures appeared to be better predictors of toxicity outcomes than mean heart dose (MHD) or whole-heart V30Gy. These findings have implications for reducing coronary events through radiation therapy planning.